SCHEMBL1790668

SCHEMBL1790668

C[C@@H](N)c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.62
CA2 P00918 16/20 0.54
CA1 P00915 13/20 0.54
CA9 Q16790 12/20 0.54
CA12 O43570 10/20 0.54
CA7 P43166 7/20 0.54
CA5A P35218 6/20 0.54
CA5B Q9Y2D0 6/20 0.54
CA6 P23280 3/20 0.54
CA3 P07451 2/20 0.54
CA4 P22748 4/20 0.50
CA14 Q9ULX7 3/20 0.50
CA13 Q8N1Q1 2/20 0.50
USP2 O75604 1/20 0.50
TSHR P16473 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
AGO2 Q9UKV8 1/20 0.50
ADRB2 P07550 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1186051 1.00 ALDH1A1 (0.62) ALDH1A1CA2CA1CA9CA12
SCHEMBL8248221 1.00 ALDH1A1 (0.62) ALDH1A1CA2CA1CA9CA12
Hydrochloric Acid SCHEMBL2352018 0.98 ALDH1A1 (0.60) ALDH1A1CA2CA1CA9CA12
SCHEMBL24152552 0.84 ALDH1A1 (0.55) ALDH1A1TSHRADRB2
SCHEMBL84516 0.84 CA2 (0.68) ALDH1A1CA2CA1CA9CA12
Hydrochloric Acid SCHEMBL3532247 0.82 CA2 (0.66) ALDH1A1CA2CA1CA9CA12
Fluoride SCHEMBL28353367 0.82 CA2 (0.66) ALDH1A1CA2CA1CA9CA12
SCHEMBL14211437 0.82 ENPP2 (0.48) ALDH1A1ADRB2
SCHEMBL9423733 0.82 CA2 (0.66) ALDH1A1CA2CA1CA9CA12
SCHEMBL8182080 0.82 ENPP2 (0.48) ALDH1A1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4034094-B1 PHOSPHODIESTERASE INHIBITORS AND USE ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) 2026-04-15 EP disclosed
CN-115151253-B Phosphodiesterase inhibitors and uses 南京征祥医药有限公司 2025-04-15 CN disclosed
CN-116574099-A Phosphodiesterase inhibitors and uses 南京征祥医药有限公司 2023-08-11 CN disclosed
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-06-13 US disclosed
US-20230014730-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2023-01-19 US disclosed
CN-115151253-A Phosphodiesterase inhibitors and uses thereof 南京征祥医药有限公司 2022-10-04 CN disclosed
EP-4034094-A1 PHOSPHODIESTERASE INHIBITORS AND USE Nanjing Zhengxiang Pharmaceuticals Co., Ltd. (CN) 2022-08-03 EP disclosed
US-20220220114-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2022-07-14 US disclosed
WO-2021061803-A1 PHOSPHODIESTERASE INHIBITORS AND USE NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2021-04-01 WO disclosed
US-8536187-B2 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2013-09-17 US disclosed
US-8536187-B2 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2013-09-17 US disclosed
US-8536187-B2 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2013-09-17 US disclosed
US-20110123493-A1 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2011-05-26 US disclosed
US-20110123493-A1 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2011-05-26 US disclosed
US-20110123493-A1 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2011-05-26 US disclosed
WO-2010002998-A1 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110123493-A1 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, CYP2S1, DPYD ALDH1A1 732/4885CA2 3079/4885CA1 4693/4885
US-11673889-B2 Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors ENPP1, ENPP3, PDE4A ALDH1A1 518/4885CA2 3011/4885CA1 4735/4885
US-20220220114-A1 PHOSPHODIESTERASE INHIBITORS AND USE ENPP1, ENPP3, PDE4A ALDH1A1 1493/4885CA2 2126/4885CA1 4390/4885
US-20230014730-A1 PHOSPHODIESTERASE INHIBITORS AND USE ENPP1, ENPP3, PDE4A ALDH1A1 1493/4885CA2 2126/4885CA1 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.